Federica Di Nicolantonio, PhD, University of Torino, Turin, Italy, discusses results from the Phase II CUPISCO (NCT03498521) trial which compared the safety and efficacy of targeted therapy or immunotherapy guided by genomic profiling (molecularly-guided therapy, MGT) versus platinum-based chemotherapy in patients with unfavorable cancer of unknown primary (CUP). In patients who achieved disease control after three cycle of first-line platinum-based induction chemotherapy, MGT improved progression-free survival (PFS) compared to patients who continued with further chemotherapy cycles. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
